gMG Connect
  • Saved

7mo
Health Literacy in Patients With Myasthenia Gravis: A Cross-Sectional Study - PubMed

Health Literacy in Patients With Myasthenia Gravis: A Cross-Sectional Study - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/41527741/

Symptom-burdened patients and centres without specialized nursing support appear to be priority targets for HL-oriented interventions and organizational redesign.

Cross-sectional Italian study finds problematic health literacy in adults with myasthenia gravis, with lower scores linked to symptom burden and improved domains associated with specialized nursing support in neurology centers.

  • Saved

7mo
Health Literacy in Patients With Myasthenia Gravis: A Cross-Sectional Study - PubMed

Health Literacy in Patients With Myasthenia Gravis: A Cross-Sectional Study - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/41527741/

Symptom-burdened patients and centres without specialized nursing support appear to be priority targets for HL-oriented interventions and organizational redesign.

  • Saved

7mo
Post Hoc, Sex-Specific Subgroup Analysis of Efgartigimod in Patients With Generalized Myasthenia Gravis From the ADAPT Trial: A Sex and Gender Equity in Research (SAGER) Guidelines Approach - PubMed

Post Hoc, Sex-Specific Subgroup Analysis of Efgartigimod in Patients With Generalized Myasthenia Gravis From the ADAPT Trial: A Sex and Gender Equity in Research (SAGER) Guidelines Approach - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/41517964/

The ADAPT trial is registered on ClinicalTrials.gov (NCT03669588).

Post hoc ADAPT trial analysis shows comparable efficacy, safety, and quality-of-life improvements with efgartigimod in female and male AChR-antibody–positive generalized myasthenia gravis patients, supporting sex-equitable treatment response.

  • Saved

7mo
BCMA/CD19 CAR T cell therapy for refractory myasthenia gravis: Proteomic signatures and single-cell transcriptomics of disease flares - PubMed

BCMA/CD19 CAR T cell therapy for refractory myasthenia gravis: Proteomic signatures and single-cell transcriptomics of disease flares - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/41481736/

Myasthenia gravis (MG) is an autoimmune disorder characterized by B cell dysfunction. Here, we designed B cell maturation antigen (BCMA)/CD19 chimeric antigen receptor T cell (CAR T cell) therapy for...

Study demonstrates BCMA/CD19 CAR T cell therapy induces durable, drug-free remission in refractory myasthenia gravis, with B-cell reconstitution patterns, proteomic shifts, and FCRL5 identified as a potential relapse biomarker.

  • Saved

argenx

Sponsored

Discover My VYVGART® Path, a comprehensive patient support program

Get personalized support throughout your patient's treatment journey. Enroll your patients online or via fax and get them started with VYVGART Hytrulo or VYVGART.

Advertisement

argenx logo

For US audiences only.

VYVGART and VYVGART Hytrulo are registered trademarks of argenx.

© 2025 argenx US-VYV-25-00177 V1 11/2025. All Rights Reserved.